Safety Study of Ziprasidone (Geodon) for the Depressive Mixed State
Information source: Tufts Medical Center
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Bipolar Disorder; Bipolar Depression; Depression
Intervention: ziprasidone (Geodon) (Drug); placebo (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: Tufts Medical Center Official(s) and/or principal investigator(s): Nassir Ghaemi, MD, MPH, Principal Investigator, Affiliation: Tufts University
Summary
Mixed states in bipolar disorder have long been recognized. Over a century ago, it was
argued that mixed states were the most common episodes in manic-depressive illness. A mixed
state is defined as a person who is experiencing symptoms of both depression and mania.
Currently, a person must have depression plus 3 or more manic symptoms for the episode to be
diagnosed mixed. Using this narrow view, less than 10% of episodes in patients with bipolar
disorder would meet criteria for a mixed episode. A broader view requires that the person
have at least 2 manic symptoms. Using this broader view, data suggest that about 50% of
episodes in bipolar disorder would be diagnosable as mixed states.
Studies suggest that the majority of persons with a depressive mixed state have bipolar
disorder type II. Many people who have a mixed state will also have major depression. Even
with such high potential rates of mixed episodes in both bipolar disorder and major
depression, there have been few studies addressing the issue.
The purpose of this study is to look at how effective Geodon is in treating the depressive
mixed state in people with bipolar or major depression. This will be the first clinical
trial that is both double-blind and randomized.
Clinical Details
Official title: Double-blind, Placebo-controlled Trial of Ziprasidone (Geodon) for the Depressive Mixed State
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Primary outcome: The Primary Outcome Measure Was Change in Montgomery-Asberg Depression Rating Scale (MADRS) Scores Over Weeks Between Groups.
Detailed description:
We plan on enrolling 25 subjects from each of the four sites. After signing a consent form,
subjects will be screened and asked to have a physical and specific safety labs done to make
sure they can safely participate in the study. After the screening visit, subjects will be
randomly, like a flip of a coin, placed into one of two groups. One group will get the
study drug, Geodon. The other group will get placebo, a sugar pill. Neither the doctor nor
subject will know in which group the subject has been placed.
Subjects will see the doctor once a week for 6 weeks. During each visit, we will check and
treat any side effects. We will ask questions about mood and go through a number of rating
scales and assessments that will look at mood and symptoms. Subjects will also fill out
questionnaires at each visit to assess their moods and see how the study is going. At the
final visit, subjects will have the same physical exam and lab tests done as in the initial
visit.
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Diagnosis of bipolar disorder type II, or unipolar major depressive disorder
- If female, non-pregnant/non-lactating
- If a sexually active female of reproductive potential, must be using adequate
contraception (i. e., oral contraceptives, barrier protection, or prior tubal
ligation)
- Currently meets DSM-IV criteria for a major depressive episode, and presence of 2 or
3 DSM-IV manic criteria, present for the majority of the time during the past week.
- All other baseline psychotropic drugs will be allowed to be continued unchanged.
However, if antidepressant use has been initiated in the previous 2 months, or was
thought to be contributing to the depressive mixed state, then antidepressant
medications would be discontinued 4 weeks before starting the study.
Locations and Contacts
Northwestern University, Chicago, Illinois 60201, United States
Tufts University, Boston, Massachusetts 02111, United States
Cambridge Health Alliance, Cambridge, Massachusetts 02139, United States
Duke University, Durham, North Carolina 27704, United States
Additional Information
Starting date: December 2006
Last updated: November 19, 2013
|